ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Oxford Biomedica PLC A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.	United Kingdom	OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.	United Kingdom	OCTHF
Pacira BioSciences, Inc. Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.	United States of America	PCRX
PAINREFORM LTD. Specialty pharma developing extended-release drugs for post-operative pain management.	United States of America	PRFX
PAION AG Developed drugs for hospital-based sedation, anesthesia, and critical care.	Germany	PA8
PALISADE BIO, INC. Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.	United States of America	PALI
PALVELLA THERAPEUTICS, INC. Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.	United States of America	PVLA
Pangen Biotech Inc. Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.	South Korea	222110
Pasithea Therapeutics Corp. Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.	United States of America	KTTA
Pelthos Therapeutics Inc. Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.	United States of America	PTHS